about
Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort studyComparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City CohortA prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal womenA prospective study of diurnal cortisol and cognitive function in community-dwelling elderly people.Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence.Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia.Metabolic syndrome, its components, and mortality in the elderlyNeurological signs and late-life depressive symptoms in a community population: the ESPRIT study.Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort studyMetabolic syndrome and onset of depressive symptoms in the elderly: findings from the three-city study.Long-term post-operative cognitive decline in the elderly: the effects of anesthesia type, apolipoprotein E genotype, and clinical antecedents.A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study.Association of adverse childhood environment and 5-HTTLPR Genotype with late-life depression.Hypnotics and mortality in an elderly general population: a 12-year prospective study.COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groupsC-reactive protein gene variants: independent association with late-life depression and circulating protein levelsInsomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly.Involvement of GPR50 polymorphisms in depression: independent replication in a prospective elderly cohort.Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study)Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort studyThe Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration.BDNF promoter methylation and genetic variation in late-life depression.Excessive sleepiness is predictive of cognitive decline in the elderlyAge-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study.Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort studyGlycemia, insulin resistance, insulin secretion, and risk of depressive symptoms in middle age.Oestrogen receptor polymorphisms and late-life depression.Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence.Hormonal treatment, mild cognitive impairment and Alzheimer's diseaseLifetime hormonal factors may predict late-life depression in women.Lipid lowering agents, cognitive decline, and dementia: the three-city study.Modelling complex pathways between late-life depression and disability: evidence for mediating and moderating factors.Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression.Biological and psychological predictors of posttraumatic stress disorder onset and chronicity. A one-year prospective study.Preliminary evidence for a role of the adrenergic nervous system in generalized anxiety disorder.
P50
Q28730966-DE3B4896-6E89-44DD-ADDA-5D3FB61AE780Q33412222-B79DC82F-772F-422D-B367-03DD182A6BB6Q33582388-1469D4EE-6044-4EBB-A00F-F807684C72F8Q33622200-8A74919C-9F97-43A5-A23E-CCBB84DA16E9Q33952157-6DCD7852-6CFF-404D-9E1A-CC95EF1F0839Q34047968-44C5818F-CC20-4DBC-9BF0-4FDE1F461F14Q34088937-A610681C-00EB-4BA8-8756-F42629F39105Q34104256-B58BE01E-5C0C-46A0-9F14-B9588D4AEF47Q34231191-3D7B5F0B-1E5C-4FF3-8879-DB84359F8A3DQ34262473-219C8DBD-B312-4232-908C-70B23C635BD7Q34305987-7000360D-FF27-449E-B2AA-023EEDCA7F9AQ34361818-77D6E450-05EC-4870-A8C4-36BC738D178DQ34383175-3BBAF9F3-C18D-4E97-89E7-F40C2C7550BEQ34407945-68EFEC0E-8736-423B-9666-5C1659CEB191Q34718421-0E5A5E71-2DED-49D3-8053-CA545819D81EQ34806075-061D279D-75FB-4DFB-83DB-F10F617D442AQ34806089-1E22742B-B5DE-4033-86C2-895E821EA3BEQ34806098-7BA6B635-3ECE-452A-9A8D-03FAE873F06EQ35000200-69E14EAB-A22A-4A16-949E-76C284F27DB5Q35032898-27E6787C-4EBD-48A0-88F4-D1EBF6D4FFFEQ35034809-2A2FC885-2D91-4414-8060-48C5788FADE8Q35110572-D9C16722-69F0-41B7-BBBE-BB3ACC32CA7DQ35169137-A2C6709E-66AF-4181-A250-5C64480F7EF0Q35598788-DE32FAE6-7854-463C-98BE-0B60221431A7Q35622601-C7AC4439-4599-42D9-A12A-AD325FBD8F31Q35833343-2C188212-2CA5-463F-B49F-3B708810A5C7Q36043366-B428A060-E2A8-42BB-B969-E823797F6876Q36147041-618E492D-86A7-46BE-A8B2-E4A0820E6CE3Q36316316-F0F753E1-E558-4774-8F47-D88B4EA1DD92Q36325378-6DCCBE1C-8A02-46FD-B8C0-2936BFD787AAQ36720395-EDE29D35-F784-453E-9142-16D791EFFFBBQ36758664-EBA5F55B-55E9-4461-9E8F-093E2D4711FDQ36818461-EDAC7A3C-0D8A-4B86-B546-74A1F6C2CD3BQ37029421-D81593AA-BD8D-4BCA-9F32-7CDF47BFE5F3Q37032563-DBEE7115-C740-4A60-B425-A39ED49601B5Q37095998-9F85AAD9-1DED-49EF-B370-BD7619678722Q37214462-80CBAD90-490C-4881-A057-4EBF8C019AECQ37362345-0CAD30B0-CF4C-4A06-8D4A-E65BA0326E4FQ37486858-4FE5C5A4-D4D5-481F-BAEA-CB960E6EAFBBQ37642812-4968F7A0-30A4-4708-BE17-4746EA870AE7
P50
description
researcher ORCID ID = 0000-0002-1149-4320
@en
wetenschapper
@nl
name
Marie-Laure Ancelin
@ast
Marie-Laure Ancelin
@en
Marie-Laure Ancelin
@es
Marie-Laure Ancelin
@nl
type
label
Marie-Laure Ancelin
@ast
Marie-Laure Ancelin
@en
Marie-Laure Ancelin
@es
Marie-Laure Ancelin
@nl
prefLabel
Marie-Laure Ancelin
@ast
Marie-Laure Ancelin
@en
Marie-Laure Ancelin
@es
Marie-Laure Ancelin
@nl
P31
P496
0000-0002-1149-4320